Lumonus has successfully closed a Series B financing round, raising A$25 million to expand its AI-powered radiation oncology workflow solutions globally. The funding, announced on November 7, 2025, was led by Aviron Investment Management, with continued support from Oncology Ventures. This investment underscores the growing clinical adoption of Lumonus’ technology across leading health systems in the United States, Australia, and Europe.
The Lumonus AI platform has already facilitated over 280,000 cancer treatments and automated the creation of more than 75,000 cancer treatment plans. These achievements highlight the platform’s effectiveness in streamlining essential oncology workflows, ultimately improving care efficiency and consistency.
Leadership and Vision in Oncology Innovation
The leadership team at Lumonus brings over 100 years of combined experience in clinical, operational, and technical roles from cancer centers worldwide. This extensive background informs the company’s commitment to delivering solutions that empower care teams to provide high-quality treatment.
Keith Hansen, Chief Executive Officer of Lumonus, emphasized the current pivotal moment in oncology, stating, “Scientific innovation in cancer treatment has advanced significantly, but the systems that support teams delivering the care have not kept pace.” He added that the integration of AI-native architecture and an end-to-end workflow approach is essential for reimagining oncology practices. Hansen noted that this funding will enable Lumonus to expand its team and assist more health systems in adopting innovative solutions.
Chairman Merrick Howes also expressed pride in the team’s dedication, saying, “This milestone reflects the dedication of our entire team, who have worked side by side with clinicians worldwide to demonstrate real impact in oncology today.” He highlighted the platform’s proven ability to enhance clinical quality and operational efficiency, and noted that the new capital would accelerate product innovation and expand Lumonus’ market presence in the United States.
Strategic Growth and Future Initiatives
The funds from this Series B round will primarily be allocated to enhancing Lumonus’ U.S. go-to-market strategies and clinical success teams. The company plans to advance its flagship products, including Lumonus AI Physician and Lumonus AI Dosimetry. Additionally, investments will be made in clinical informatics capabilities to improve operational performance and deliver more personalized, data-driven care.
Ben Freeberg, Managing Partner at Oncology Ventures, praised the Lumonus team for their blend of clinical expertise and product execution. He stated, “The Lumonus team combines deep clinical expertise with world-class product execution and has already earned the trust of leading cancer centers internationally.” This backing reflects a commitment to making measurable impacts in oncology and setting new standards for workflow efficiency.
The company’s collaborations with health systems will focus on harnessing real-world evidence to enhance care quality and accessibility. This approach aims to improve operational performance while providing personalized treatment options for cancer patients.
For more information about Lumonus and its innovative solutions, visit www.lumonus.com.
